No Carolina / NY / Florida
Ph: 561.316.3330

Cedars-Sinai and Smidt Heart Institute Study, Presented at European Society of Cardiology Congress 2022, Shows Artificial Intelligence Can Better Assess and Diagnose Cardiac Function

Summation

  • In a first-of-its-kind randomized clinical trial led by researchers at the Smidt Heart Institute and the at Cedars-Sinai, artificial intelligence (AI) proved more successful in assessing and diagnosing cardiac function when compared to echocardiogram assessments made by sonographers.
  • “When developed in the right way, artificial intelligence offers the opportunity to improve the quality of echocardiogram readings as well as increase efficiencies in the time and effort spent by busy cardiologists and sonographers alike.
  • Said David Ouyang, MD, a cardiologist in the Department of Cardiology in the Smidt Heart Institute and principal investigator of the study, known as EchoNet-RCT.

In a first-of-its-kind randomized clinical trial led by researchers at the Smidt Heart Institute and the at Cedars-Sinai, artificial intelligence (AI) proved more successful in assessing and diagnosing cardiac function when compared to echocardiogram assessments made by sonographers.

The results, announced today during a late-breaking presentation at the European Society of Cardiology Congress 2022, have immediate translational implications for patients undergoing cardiac function imaging and broader implications for the field of cardiac imaging.

“This is the first randomized clinical trial of artificial intelligence in cardiology,” said David Ouyang, MD, a cardiologist in the Department of Cardiology in the Smidt Heart Institute and principal investigator of the study, known as EchoNet-RCT. “With this new knowledge, we hope to improve the quality and effectiveness of echocardiogram imaging for patients everywhere.”

Previously, researchers at the Smidt Heart Institute and Stanford University developed one of the first artificial intelligence technologies to assess cardiac function, specifically, left ventricular ejection fraction-the key heart measurement used in diagnosing cardiac function. Their research was published in the prestigious journal Nature.  

Building on this past research, the most recent study assessed the impact of artificial intelligence in clinical deployment as part of a prospective, blinded and randomized controlled clinical trial.

There has been much excitement about the use of AI in medicine, but the technologies are rarely assessed in prospective clinical trials,” said Ouyang. “This trial was powered to show non-inferiority of the AI compared to sonographer tracings, and so we were pleasantly surprised when the results actually showed superiority for AI with respect to the pre-specified outcomes.”

In the study, Cedars-Sinai cardiologists evaluated 3,495 transthoracic echocardiogram studies, comparing initial assessment by artificial intelligence or by a sonographer-also known as an ultrasound technician.

One of the major findings was that cardiologists more frequently agreed with the AI initial assessment, such that they corrected only 16.8% of the initial assessments made by AI and simultaneously corrected 27.2% of the initial assessments made by the sonographers. This difference demonstrated not only non-inferiority but actually superiority of AI.

The research team also discovered that cardiologists were unable to distinguish between initial assessments made by the AI and sonographers.

“We asked our cardiologist over-readers to guess if they thought the tracing they had just reviewed was performed by AI or by a sonographer, and it turns out that they couldn’t tell the difference,” said Ouyang. “This speaks to the strong performance of the AI algorithm as well as the seamless integration into clinical software. We believe these are all good signs for future trial research in the field.”

Additionally, the Smidt Heart Institute research team learned that this type of clinical trial can be seamlessly integrated into the standard clinical workflow.

“We are excited by the implications of this clinical trial and what it means for the future of artificial intelligence and cardiology,” said Susan Cheng, MD, MPH, director of the Institute for Research on Healthy Aging in the Department of Cardiology at the Smidt Heart Institute and EchoNet-RCT investigator. “When developed in the right way, artificial intelligence offers the opportunity to improve the quality of echocardiogram readings as well as increase efficiencies in the time and effort spent by busy cardiologists and sonographers alike.”

As a next step, Ouyang says the Smidt Heart Institute team plans to evaluate how AI analysis applied to Cedars-Sinai echocardiogram imaging procedures may improve clinical outcomes.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

- Advertisement -

spot_img

- Advertisement -

New Inflammatory Bowel Disease Center Opens at Northwell Health

The new Inflammatory Bowel Disease Center, located at 125 Community Drive in Manhasset, has 13 exam rooms, two procedural rooms and six infusion bays. Since it started operations, people have travelled from all over the country – and as far away as Alaska – to receive high-quality care.

Cold Spring Harbor Laboratory and Northwell Health Extend Strategic Affiliation

“The alliance between Cold Spring Harbor Laboratory (CSHL) and Northwell Health brings transformative bioscience research into the clinic,” says CSHL President & CEO Bruce Stillman. “As New York’s largest healthcare provider, Northwell Health serves a remarkably diverse patient population. This agreement will provide patient communities with greater access to cutting-edge biomedical technology, allowing for more precise diagnoses and treatments, and ultimately facilitating new breakthroughs in cancer care.”

Hackensack Meridian Neuroscience Institute at JFK University Medical Center Receives $2.2 Million Research Grant to Study A Novel Traumatic Brain Injury Treatment

The NIH grant will fund a project entitled “Neutrophil Extracellular Traps And Associated Pathogenesis In TBI: A Novel Peptide Therapeutic Strategy” proposed by Mohammed Abdul Muneer, MSc, PhD, Research Scientist & Principal Investigator, Hackensack Meridian Neuroscience Institute at JFK University Medical Center, and Associate Professor of Neurology at the Hackensack Meridian School of Medicine.

By using this website you agree to accept Medical Device News Magazine Privacy Policy